(Adds deal details with Lupin , Sun Pharma; quote from Lilly India MD)
BENGALURU, May 10 (Reuters) - Eli Lilly (NYSE: LLY ) and Co LLY.N said on Monday it had signed licensing agreements with three Indian generic drugmakers to expand the availability of its arthritis drug baricitinib in the country for treating COVID-19 patients.
The agreements will bolster India's arsenal of drugs to battle its catastrophic second wave of the pandemic, which has led to an acute shortage of coronavirus medicines including remdesivir and tocilizumab.
Baricitinib has been given restricted emergency use approval by India's drug regulator for use in combination with remdesivir for the treatment of hospitalised COVID-19 adult patients requiring supplemental oxygen, Eli Lilly said in an emailed statement.
The U.S. Food and Drug Administration initially gave Lilly an emergency use approval in November for baricitinib in combination with remdesivir to treat COVID-19 patients. licenses to additional Indian generic manufacturers are expected to be announced soon," said Luca Visini, managing director at Lilly India, without elaborating further.
Last week, Lilly said it would donate 400,000 tablets of baricitinib, to be used with remdesivir, to the Indian government. agreements would expand the portfolio of COVID-19 drugs offered by the country's drugmakers. All three companies offer antiviral drug favipiravir, used to treat patients with moderate to mild COVID-19.
Cipla, which also offers remdesivir and tocilizumab, said last week it would be the local distribution partner for a COVID-19 antibody drug cocktail developed by Roche ROG.S and Regeneron REGN.O , after the therapy got domestic emergency use approval. smaller Indian drugmaker Natco Pharma NATP.NS said https:// earlier this month it would request a compulsory license based on emergency approval for its own generic version of baricitinib.
India reported 366,161 new infections and 3,754 deaths on Monday, dipping from recent peaks, while calls grew for a nationwide lockdown.
Add Chart to Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
- Enrich the conversation
- Stay focused and on track. Only post material that’s relevant to the topic being discussed.
- Be respectful. Even negative opinions can be framed positively and diplomatically.
- Use standard writing style. Include punctuation and upper and lower cases.
- NOTE: Spam and/or promotional messages and links within a comment will be removed
- Avoid profanity, slander or personal attacks directed at an author or another user.
- Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
- Only English comments will be allowed.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.